A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma
A Cell-Free tsRNA-Based Liquid Biopsy Signature for Early Detection of Hepatocellular Carcinoma
City of Hope Medical Center
600 participants
Jan 15, 2025
OBSERVATIONAL
Conditions
Summary
Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a cell-free tsRNA (cf-tsRNA)-based liquid biopsy assay for accurate detection of early-stage HCC.
Eligibility
Inclusion Criteria3
- A histologically confirmed diagnosis of hepatocellular carcinoma.
- Received standard diagnostic and staging procedures as per local guidelines
- Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment
Exclusion Criteria1
- • Lack of or inability to provide informed consent
Interventions
Comprehensive small RNA sequencing of serum or plasma-derived cf-tsRNAs to identify candidate biomarkers distinguishing HCC from NDC.
Construction of integrated cf- tsmiRNAs diagnostic classifier using machine learning
PCR-based validation of the tsRNA panel
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07265271